细胞免疫成分TRIM5α和APOBEC3G抗HIV-1作用机制的研究进展
被引量：1
摘要
近期备受关注的细胞内在抗逆转录病毒因子包括TRIM5a（tripartite motif protein5-alpha，TRIM5α）和载脂蛋白BmRNA编辑酶催化多肽样蛋白3G（apolipoprotein B mRNA—editing enzyme-catalytic polypeptide—like 3G，APOBEC3G），它们抗病毒的作用机制正在从不同的角度进行研究，很多工作还在继续。
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2007年第3期299-300,共2页
Chinese Journal of Experimental and Clinical Virology
基金
国家自然科学基金资助项目（30400368）
北京工业大学博士启动基金
参考文献18
-
1Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-I infection in Old World monkeys. Nature, 2004, 427: 848-853.
-
2Song B, Gold B, O'hUigin C, et al. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5α exhibits lineage-specific length and sequence variation in primates. J Virol, 2005, 79: 6111-6121.
-
3Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J, 2001, 20: 2140-2151.
-
4Rhodes DA, de Bono B, Trowsdale J. Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence? Immunology, 2005,116:411-417.
-
5Javanbakht H, Diaz-Griffero F, Stremlau M, et al. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIMSalpha. J Biol Chem, 2005, 280:26933-26940.
-
6Owens CM, Song B, Perron MJ, et al. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol, 2004, 78: 5423-5437.
-
7Luban J, Bossolt KL, Franke EK, et al. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell, 1993, 73: 1067-1078.
-
8Hatziioannou T, Perez-Caballero D, Cowan S, et al. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol, 2005, 79: 176-183.
-
9Si Z, Vandegraaff N, O'Huigin C, et al. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A, 2006, 103: 7454-7459.
-
10Yap M, Dodding MP, Stoye JP. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J Virol, 2006, 80: 4061-4067.
同被引文献22
-
1Jiang SSP,Liu S. Blocking of viral entry,a complimentary strategy for HIV therapy[J].Drug Discov Today:Therstrateg,2004,(04):497-503.
-
2Cocchi F,DeVico AL,Garzino-Demo A. Identification of RANTES,MIP-1 alpha,and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells[J].Science,1995,(5243):1811-1815.
-
3Schols D,Prooet P,Struyf S. CD26-processed RANTES(3-68),but not intact RANTES,has potent anti-HIV-1 activity[J].Antiviral Research,1998,(03):175-187.doi:10.1016/S0166-3542(98)00039-4.
-
4Mack M,Luckow B,Nelson PJ. Aminooxypentane-RANTES induces CCR5 internalizatinn but inhibits recycling:a novel inhibitory mechanism of HIV infectivity[J].Journal of Experimental Medicine,1998,(08):1215-1224.doi:10.1084/jem.187.8.1215.
-
5Lederman MM,Veazey RS,Offord R. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5[J].Science,2004,(5695):485-487.doi:10.1126/science.1099288.
-
6Ramnarine EJ,Devieo AL,Vigil-Cruz SC. Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibit HIV-1 infectivity[J].Bioorganic and Medicinal Chemistry Letters,2006,(01):93-95.doi:10.1016/j.bmcl.2005.09.044.
-
7Yang OO,Swanberg SL,Lu Z. Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1 beta correlates with down-modulation of GXCR4[J].Journal of Virology,1999,(06):4582-4589.
-
8Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function[J].Journal of General Virology,2001,(Pt 8):1807-1814.
-
9Boggiano C,Jiang S,Lu H. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor[J].Biochemical and Biophysical Research Communications,2006,(04):909-915.doi:10.1016/j.bbrc.2006.06.150.
-
10Huthoff H,Malim MH. Cytidine deamination and resistance to retroviral infection:towards a structural understanding of the APOBEC proteins[J].Virology,2005,(02):147-153.doi:10.1016/j.virol.2005.01.038.
-
1李爱君,乔秀丽,滕海风,张剑,张静.慢性肺原性心脏病病人血清补体C_3、C_4水平变化及临床意义[J].滨州医学院学报,2003,26(1):63-63.
-
2倪秀兰,王爱华,李晴.肾综合征出血热休克期的治疗[J].哈尔滨医药,2009,29(2):37-37.
-
3Van Der Molen R.G.,Sprengers D.,Binda R.S.,樊菁.慢性乙肝患者髓样与浆细胞样树突状细胞功能障碍[J].世界核心医学期刊文摘（胃肠病学分册）,2005,0(2):44-44.
-
4蔡卫平.The mRNA expression of apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G in peripheral blood mononuclear cells in patients with chronic hepatitis C and its regulation by interferon-α[J].China Medical Abstracts(Internal Medicine),2013,30(1):14-14.
-
5金珊珊,胡爱荣.核苷（酸）类似物与干扰素联合治疗慢性乙型肝炎的进展[J].中华传染病杂志,2016,34(10):638-640. 被引量：4
-
6韩思源,林菊生,林园园,常莹,姚津剑.APOBEC3G体外抗乙型肝炎病毒的研究[J].胃肠病学和肝病学杂志,2007,16(2):152-155. 被引量：1
-
7王福祥,毕蔓茹,颜丙柱,周慧,刘卫华,李用国,周晋.HIV/AIDS患者APOBEC3G mRNA水平与CD4T淋巴细胞计数相关研究[J].哈尔滨医科大学学报,2011,45(2):138-141. 被引量：3
-
8周炳华,普雄明,吴卫东,靳颖,罗小军.ＳＬＥ患者狼疮带试验中各免疫成分的分析[J].中华临床医药杂志（北京）,2002,3(20):59-60.
-
9樊博,岑山,蒋建东.APOBEC3G抗HIV-1的分子机制研究进展[J].药学学报,2008,43(7):678-682. 被引量：2
-
10项晓刚,谢青.HBV和HCV重叠感染的治疗进展[J].中国医学前沿杂志（电子版）,2008(2):40-43.
